Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

BMS signs large-molecule licensing agreement with Ambrx

28 Aug 2019

Executive Summary

Ambrx Inc. (protein therapeutics and antibody-drug conjugates) has licensed Bristol-Myers Squibb Co. exclusive global rights to research, develop, and market modified forms of fibroblast growth Factor 21 (FGF-21) for Type II diabetes, and relaxin for heart failure, both currently in preclinical. NOTE: The FGF-21 therapeutic, also known as BMS986036, is also being tested in liver fat, liver injury, and fibrosis in nonalcoholic steatohepatitis patients.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
    • Synthesis Technologies, Production Processes
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By